World's Best Scientists 2026 revealed!

D-Index & Metrics

Microbiology

D-Index
61
Citations
32830
World Ranking
2940
National Ranking
1169

Overview

Robert W. Frenck is affiliated with Cincinnati Children's Hospital Medical Center in the United States. Their research primarily focuses on medicine, with a significant emphasis on infectious diseases, epidemiology, health, endocrinology, and molecular biology.

Their work covers diverse topics including:

  • SARS-CoV-2 and COVID-19 Research
  • Viral gastroenteritis research and epidemiology
  • Vaccine Coverage and Hesitancy
  • Respiratory viral infections research
  • Influenza Virus Research Studies
  • Escherichia coli research studies
  • Clostridium difficile and Clostridium perfringens research

Frequent coauthors involved in their publications include:

  • Kathleen M. Neuzil
  • Kristina A. Bryant
  • William C. Gruber
  • Nicholas Kitchin
  • James D. Campbell

Their most common publication venues are:

  • PEDIATRICS
  • New England Journal of Medicine
  • bioRxiv (Cold Spring Harbor Laboratory)
  • mSphere
  • The Pediatric Infectious Disease Journal

Recent significant papers authored or coauthored by Robert W. Frenck include:

  • Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine, 2020, New England Journal of Medicine
  • Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates, 2020, New England Journal of Medicine
  • Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults, 2020, Nature
  • Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents, 2021, New England Journal of Medicine
  • Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age, 2021, New England Journal of Medicine

The body of work indicates an ongoing involvement in vaccine research and epidemiological studies on viral infections, with a notable contribution to understanding and evaluating COVID-19 vaccines across different age groups.

Best Publications

  • Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.

    Fernando P. Polack;Stephen J. Thomas;Nicholas Kitchin;Judith Absalon

  • Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.

    Edward E. Walsh;Robert W. Frenck;Ann R. Falsey;Ann R. Falsey;Nicholas Kitchin

  • Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults.

    Mark J. Mulligan;Kirsten E. Lyke;Nicholas Kitchin;Judith Absalon

  • Homologous and Heterologous Covid-19 Booster Vaccinations

    Unknown

  • Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents.

    Robert W Frenck;Nicola P Klein;Nicholas Kitchin;Alejandra Gurtman

  • Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months.

    Stephen J. Thomas;Edson D. Moreira;Nicholas Kitchin;Judith Absalon

  • The Rate of Telomere Sequence Loss in Human Leukocytes Varies with Age

    Robert W. Frenck;Elizabeth H. Blackburn;Kevin M. Shannon

  • Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age.

    Emmanuel B. Walter;Kawsar R. Talaat;Charu Sabharwal;Alejandra Gurtman

  • Helicobacter in the developing world

    Robert W. Frenck;John Clemens

  • Policy statement - Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections

    Joseph A. Bocchini;Henry H. Bernstein;John S. Bradley;Michael T. Brady

  • Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses.

    Gil Y Melmed;Andrew F Ippoliti;Konstantinos A Papadakis;Tram T Tran

  • SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3.

    Ann R Falsey;Robert W Frenck;Edward E Walsh;Nicholas Kitchin

  • Norovirus Vaccine Against Experimental Human GII.4 Virus Illness: A Challenge Study in Healthy Adults

    David I. Bernstein;Robert L. Atmar;G. Marshall Lyon;John J. Treanor

  • Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease.

    Gil Y Melmed;Nik Agarwal;Robert W Frenck;Andrew F Ippoliti

  • The use of systemic fluoroquinolones

    Keith R. Powell;Robert S. Baltimore;Henry Bernstein;Joseph A. Bocchini

  • Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older

    Lisa A. Jackson;Alejandra Gurtman;Martin van Cleeff;Robert W. Frenck

  • Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine–naïve adults 60–64 years of age

    Richard N. Greenberg;Alejandra Gurtman;Robert W. Frenck;Cynthia Strout

  • Predicting Susceptibility to Norovirus GII.4 by Use of a Challenge Model Involving Humans

    Robert Frenck;David I Bernstein;David I Bernstein;Ming Xia;Pengwei Huang

  • Pathogenicity and Convalescent Excretion of Campylobacter in Rural Egyptian Children

    Malla R. Rao;Abdollah B. Naficy;Stephen J. Savarino;Remon Abu-Elyazeed

  • Azithromycin versus Ceftriaxone for the Treatment of Uncomplicated Typhoid Fever in Children

    Robert W. Frenck;Isabelle Nakhla;Yehia Sultan;Samir B. Bassily

  • RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study

    Edward E. Walsh;Robert Frenck;Ann R. Falsey;Nicholas Kitchin

Frequent Co-Authors

William C. Gruber
William C. Gruber Pfizer (United States)
John S. Bradley
John S. Bradley University of California, San Diego
Thomas F. Wierzba
Thomas F. Wierzba Wake Forest University
David W. Kimberlin
David W. Kimberlin University of Alabama at Birmingham
Kathrin U. Jansen
Kathrin U. Jansen Pfizer (United States)
Carol J. Baker
Carol J. Baker Baylor College of Medicine
John D. Clemens
John D. Clemens University of California, Los Angeles
Daniel A. Scott
Daniel A. Scott Pfizer (United States)
Larry K. Pickering
Larry K. Pickering Emory University
Ann R. Falsey
Ann R. Falsey University of Rochester

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in microbiology, exploring related online degrees can open diverse career pathways. Fields such as healthcare, medical coding, and specialized nursing often complement microbiology's scientific foundation. Many programs offer flexible online options, making them accessible to a wider range of learners, including those with unique circumstances.

For instance, individuals curious about salary prospects and career growth might explore roles like a how much do child life specialists make. This profession blends science and patient care, similar to microbiology’s healthcare applications.

Those facing barriers to education or employment can consider online degrees for felons, which support reintegration by offering credible pathways to stable careers in science-related fields.

Healthcare practitioners interested in holistic approaches may find a career as a functional medicine nurse practitioner salary rewarding, combining patient care with innovative treatment methods rooted in biology and microbiology.

Another practical route is becoming a certified professional coder, where understanding medical terminology and biology enhances career prospects. For insights, see cpc salary and career paths.

Best Scientists Citing Robert W. Frenck

Trending Scientists

Recently Published Articles